Skip to main content
Top
Published in: Angiogenesis 3/2013

01-07-2013 | Original Paper

Reduction of connexin43 in human endothelial progenitor cells impairs the angiogenic potential

Authors: Hsueh-Hsiao Wang, Cheng-Huang Su, Yih-Jer Wu, Jiun-Yi Li, Ya-Ming Tseng, Yi-Chun Lin, Chin-Ling Hsieh, Cheng-Ho Tsai, Hung-I Yeh

Published in: Angiogenesis | Issue 3/2013

Login to get access

Abstract

Our previous work showed that arsenic trioxide down-regulated Cx43 and attenuated the angiogenic potential of human late endothelial progenitor cells (EPC). However, the relation between Cx43 and angiogenic activity of the EPC remained unclear. In the study, human late EPC were treated with siRNA specific to Cx43 (Cx43siRNA). The expression profiles as well as activity of the treated cells were examined. In parallel, the angiogenic potential of human EPC treated with Cx43siRNA was evaluated using murine hind limb ischemic model. The results showed that, in the EPC treated with Cx43siRNA, the activity of migration, proliferation, and angiogenic potential were attenuated, accompanied by reduction in vascular endothelial growth factor (VEGF) expression. In hind limb ischemia mice, EPC treated with Cx43siRNA lost the therapeutic angiogenic potential. VEGF supplementation partially recovered the activity impaired by Cx43 down-regulation. In conclusion, reduced Cx43 expression per se in the EPC causes decreased expression of VEGF and impaired angiogenic potential of the cells. Prevention of Cx43 reduction is a potential target to maintain the angiogenic potential of the EPC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tanaka K, Sata M (2007) Therapeutic application of bone marrow-derived progenitor cells for vascular diseases: magic bullets having the good without the bad? Int J Gerontol 1:10–21CrossRef Tanaka K, Sata M (2007) Therapeutic application of bone marrow-derived progenitor cells for vascular diseases: magic bullets having the good without the bad? Int J Gerontol 1:10–21CrossRef
2.
go back to reference Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMedCrossRef Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMedCrossRef
3.
go back to reference Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228PubMedCrossRef Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228PubMedCrossRef
4.
go back to reference Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95:343–353PubMedCrossRef Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95:343–353PubMedCrossRef
5.
go back to reference Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11:321–335PubMedCrossRef Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11:321–335PubMedCrossRef
6.
go back to reference Bengel FM, Schachinger V, Dimmeler S (2005) Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging 32(Suppl 2):S404–S416PubMedCrossRef Bengel FM, Schachinger V, Dimmeler S (2005) Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging 32(Suppl 2):S404–S416PubMedCrossRef
7.
go back to reference Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG, Gurtner GC (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164:1935–1947PubMedCrossRef Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG, Gurtner GC (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164:1935–1947PubMedCrossRef
8.
go back to reference Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG (2006) Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 324:475–488PubMedCrossRef Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG (2006) Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 324:475–488PubMedCrossRef
9.
go back to reference Chou Y, Tsai CH, Ueng KC, Tian TY, Chen SC, Yeh HI (2007) Endothelial gap junctions are down-regulated by arsenic trioxide. Eur J Pharmacol 569:29–36PubMedCrossRef Chou Y, Tsai CH, Ueng KC, Tian TY, Chen SC, Yeh HI (2007) Endothelial gap junctions are down-regulated by arsenic trioxide. Eur J Pharmacol 569:29–36PubMedCrossRef
10.
go back to reference Bunderson M, Coffin JD, Beall HD (2002) Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol 184:11–18PubMedCrossRef Bunderson M, Coffin JD, Beall HD (2002) Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol 184:11–18PubMedCrossRef
11.
go back to reference Kumagai Y, Pi J (2004) Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 198:450–457PubMedCrossRef Kumagai Y, Pi J (2004) Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 198:450–457PubMedCrossRef
12.
go back to reference Xiao YF, Liu SX, Wu DD, Chen X, Ren LF (2006) Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J Gastroenterol 12:5780–5786PubMed Xiao YF, Liu SX, Wu DD, Chen X, Ren LF (2006) Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J Gastroenterol 12:5780–5786PubMed
13.
go back to reference Li JY, Su CH, Wu YJ, Tien TY, Hsieh CL, Chen CH, Tseng YM, Shi GY, Wu HL, Tsai CH, Lin FY, Yeh HI (2011) Therapeutic angiogenesis of human early endothelial progenitor cells is enhanced by thrombomodulin. Arterioscler Thromb Vasc Biol 31:2518–2525PubMedCrossRef Li JY, Su CH, Wu YJ, Tien TY, Hsieh CL, Chen CH, Tseng YM, Shi GY, Wu HL, Tsai CH, Lin FY, Yeh HI (2011) Therapeutic angiogenesis of human early endothelial progenitor cells is enhanced by thrombomodulin. Arterioscler Thromb Vasc Biol 31:2518–2525PubMedCrossRef
14.
go back to reference Wang HH, Lin CA, Lee CH, Lin YC, Tseng YM, Hsieh CL, Chen CH, Tsai CH, Hsieh CT, Shen JL, Chan WH, Chang WH, Yeh HI (2011) Fluorescent gold nanoclusters as a biocompatible marker for in vitro and in vivo tracking of endothelial cells. ACS Nano 5:4337–4344PubMedCrossRef Wang HH, Lin CA, Lee CH, Lin YC, Tseng YM, Hsieh CL, Chen CH, Tsai CH, Hsieh CT, Shen JL, Chan WH, Chang WH, Yeh HI (2011) Fluorescent gold nanoclusters as a biocompatible marker for in vitro and in vivo tracking of endothelial cells. ACS Nano 5:4337–4344PubMedCrossRef
15.
go back to reference Wang HH, Kung CI, Tseng YY, Lin YC, Chen CH, Tsai CH, Yeh HI (2008) Activation of endothelial cells to pathological status by down-regulation of connexin43. Cardiovasc Res 79:509–518PubMedCrossRef Wang HH, Kung CI, Tseng YY, Lin YC, Chen CH, Tsai CH, Yeh HI (2008) Activation of endothelial cells to pathological status by down-regulation of connexin43. Cardiovasc Res 79:509–518PubMedCrossRef
16.
go back to reference Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH (2006) Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens 19:129–135PubMedCrossRef Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH (2006) Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens 19:129–135PubMedCrossRef
17.
go back to reference Yeh HI, Lai YJ, Chang HM, Ko YS, Severs NJ, Tsai CH (2000) Multiple connexin expression in regenerating arterial endothelial gap junctions. Arterioscler Thromb Vasc Biol 20:1753–1762PubMedCrossRef Yeh HI, Lai YJ, Chang HM, Ko YS, Severs NJ, Tsai CH (2000) Multiple connexin expression in regenerating arterial endothelial gap junctions. Arterioscler Thromb Vasc Biol 20:1753–1762PubMedCrossRef
Metadata
Title
Reduction of connexin43 in human endothelial progenitor cells impairs the angiogenic potential
Authors
Hsueh-Hsiao Wang
Cheng-Huang Su
Yih-Jer Wu
Jiun-Yi Li
Ya-Ming Tseng
Yi-Chun Lin
Chin-Ling Hsieh
Cheng-Ho Tsai
Hung-I Yeh
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2013
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-013-9335-z

Other articles of this Issue 3/2013

Angiogenesis 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.